Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Donna Greenberg, MD
Massachusetts General Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
43 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Puerto Rico School of Medicine Medical Sciences Campus
San Juan, Puerto Rico
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States
- Veterans Affairs Medical Center - San Diego
San Diego, California, United States
- Veterans Affairs Medical Center - Washington, Dc
Washington D.C., District of Columbia, United States
- Broward General Medical Center
Fort Lauderdale, Florida, United States
- Memorial Regional Hospital Comprehensive Cancer Center
Hollywood, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center
West Palm Beach, Florida, United States
- Louis A. Weiss Memorial Hospital
Chicago, Illinois, United States
- University of Chicago Cancer Research Center
Chicago, Illinois, United States
- West Suburban Center for Cancer Care
River Forest, Illinois, United States
- Saint Anthony Medical Center
Rockford, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Incorporated
Fort Wayne, Indiana, United States
- Baptist Hospital East - Louisville
Louisville, Kentucky, United States
- Veterans Affairs Medical Center - Baltimore
Baltimore, Maryland, United States
- Beth Israel Medical Center
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Lakeland Medical Center - St. Joseph
Saint Joseph, Michigan, United States
- Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, United States
- Barnes-Jewish Hospital
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Veterans Affairs Medical Center - Las Vegas
Las Vegas, Nevada, United States
- Cooper University Hospital
Camden, New Jersey, United States
- Elmhurst Hospital Center
Elmhurst, New York, United States
- Queens Cancer Center of Queens Hospital
Jamaica, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Ccop - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, United States
- State University of New York - Upstate Medical University
Syracuse, New York, United States
- Veterans Affairs Medical Center - Syracuse
Syracuse, New York, United States
- Veterans Affairs Medical Center - Asheville
Asheville, North Carolina, United States
- Northeast Oncology Associates
Concord, North Carolina, United States
- Veterans Affairs Medical Center - Durham
Durham, North Carolina, United States
- Cape Fear Valley Health System
Fayetteville, North Carolina, United States
- Lenoir Memorial Hospital Cancer Center
Kinston, North Carolina, United States
- Firsthealth Moore Regional Hospital
Pinehurst, North Carolina, United States
- New Hanover Regional Medical Center
Wilmington, North Carolina, United States
- Veterans Affairs Medical Center - Fargo
Fargo, North Dakota, United States
- Veterans Affairs Medical Center - Dallas
Dallas, Texas, United States
- Martha Jefferson Hospital
Charlottesville, Virginia, United States
- Virginia Oncology Associates - Norfolk
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2001
- Primary completion
- 30 Sept 2003
- Completion
- 30 Sept 2003
- Last update posted
- 4 Jul 2016
- Registered enrollment
- 21
- Registry id
- NCT00005850
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.